Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency

•Recombinant human C1-inhibitor (rhC1-INH) is an acute therapy for hereditary angioedema.•Studies found that rhC1-INH is effective as a prophylactic treatment as well.•Early administration of rhC1-INH reduces the time to the improvement and to the complete relief of symptoms.•Treatment with rhC1-INH is effective both as on-demand therapy and as short-term prophylaxis.•The repeated administration of rhC1-INH did not reduce its efficacy.